|
No.
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d) |
Exhibits
|
Press Release, dated November 9, 2021, reporting the financial results of Nuwellis, Inc. for the three and nine months ended September 30, 2021.
|
Date: November 9, 2021
|
NUWELLIS, INC.
|
||
By:
|
/s/ Nestor Jaramillo
|
||
Name:
|
Nestor Jaramillo
|
||
Title:
|
President and Chief Executive Officer
|
• |
Generated $1.9 million in total revenue, representing a decline of 3% compared to the prior-year period
|
• |
Generated $6.3 million in total revenue year-to-date through September 30, representing 16% growth compared to the prior-year period and a 52% increase above the comparable pre-pandemic period in 2019
|
• |
Opened three new pediatric accounts in the third quarter, the largest quarterly addition in 2021
|
• |
Announced R&D partnership with Koronis Biomedical Technologies Corporation (KBT) to design and develop a product for children under 20kg with limited kidney function, following a $1.7 million development grant from the National
Institutes of Health
|
• |
Completed an all-common stock capital raise of $10.0 million gross proceeds, ending the quarter with $28.4 million in cash and no debt
|
• |
Critical Care revenue more than doubled compared to the prior-year period but declined sequentially due to COVID headwinds. The Company continues to see strong utilization from key accounts that rely
heavily on the Aquadex System to treat non-COVID critically ill patients.
|
• |
Pediatric revenue declined compared to the prior-year period due to a more difficult hospital operating environment. The Company opened three new pediatric accounts in the third quarter, its largest quarterly addition in 2021, a strong sign of the interest to use the therapy among pediatric institutions.
|
• |
Heart Failure revenue increased compared to the prior year period but declined sequentially due a spike in COVID cases which negatively impacted patient behavior and access to hospitals.
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Net sales
|
$
|
1,853
|
$
|
1,904
|
$
|
6,279
|
$
|
5,397
|
||||||||
Cost of goods sold
|
733
|
1,026
|
2,682
|
2,486
|
||||||||||||
Gross profit
|
1,120
|
878
|
3,597
|
2,911
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Selling, general and administrative
|
4,645
|
4,264
|
14,945
|
13,034
|
||||||||||||
Research and development
|
1,726
|
871
|
3,847
|
2,620
|
||||||||||||
6,371
|
5,135
|
18,792
|
15,654
|
|||||||||||||
Loss from operations
|
(5,251
|
)
|
(4,257
|
)
|
(15,195
|
)
|
(12,743
|
)
|
||||||||
Other income (expense), net
|
(19
|
)
|
—
|
(22
|
)
|
—
|
||||||||||
Loss before income taxes
|
(5,270
|
)
|
(4,257
|
)
|
(15,217
|
)
|
(12,743
|
)
|
||||||||
(2
|
)
|
(3
|
)
|
(7
|
)
|
(7
|
)
|
|||||||||
Net loss
|
$
|
(5,272
|
)
|
$
|
(4,260
|
)
|
$
|
(15,224
|
)
|
$
|
(12,750
|
)
|
||||
Basic and diluted loss per share
|
$
|
(0.75
|
)
|
$
|
(2.08
|
)
|
$
|
(2.72
|
)
|
$
|
(11.27
|
)
|
||||
Weighted average shares outstanding – basic and diluted
|
7,098
|
2,049
|
5,624
|
1,287
|
||||||||||||
Other comprehensive loss:
|
||||||||||||||||
Foreign currency translation adjustments
|
$
|
—
|
$
|
(7
|
)
|
$
|
(3
|
)
|
$
|
(12
|
)
|
|||||
Total comprehensive loss
|
$
|
(5,272
|
)
|
$
|
(4,267
|
)
|
$
|
(15,227
|
)
|
$
|
(12,762
|
)
|
September 30, 2021
|
December 31, 2020
|
|||||||
ASSETS
|
(unaudited)
|
|||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$
|
28,431
|
$
|
14,437
|
||||
Accounts receivable
|
1,069
|
905
|
||||||
Inventories
|
2,805
|
2,957
|
||||||
Other current assets
|
420
|
237
|
||||||
Total current assets
|
32,725
|
18,536
|
||||||
Property, plant and equipment, net
|
1,265
|
1,200
|
||||||
Operating lease right-of-use asset
|
105
|
255
|
||||||
Other assets
|
—
|
21
|
||||||
TOTAL ASSETS
|
$
|
34,095
|
$
|
20,012
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities
|
||||||||
Accounts payable
|
$
|
1,851
|
$
|
1,097
|
||||
Accrued compensation
|
1,771
|
2,192
|
||||||
Current portion of operating lease liability
|
108
|
206
|
||||||
Current portion of finance lease liability
|
27
|
24
|
||||||
Other current liabilities
|
38
|
66
|
||||||
Total current liabilities
|
3,795
|
3,585
|
||||||
Operating lease liability
|
—
|
55
|
||||||
33
|
54
|
|||||||
Other Long-term liability
|
286
|
—
|
||||||
Total liabilities
|
4,114
|
3,694
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity
|
||||||||
Series A junior participating preferred stock as of September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 30,000 shares, none outstanding
|
—
|
—
|
||||||
Series F convertible preferred stock as of both September 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares
|
—
|
—
|
||||||
Preferred stock as of both September 30, 2021 and December 31, 2020, par value
|
—
|
—
|
||||||
Common stock as of September 30, 2021 and December 31, 2020, par value
10,537,606 and 2,736,060, respectively
|
1
|
—
|
||||||
Additional paid‑in capital
|
278,552
|
249,663
|
||||||
Accumulated other comprehensive loss:
|
||||||||
Foreign currency translation adjustment
|
(10
|
)
|
(7
|
)
|
||||
Accumulated deficit
|
(248,562
|
)
|
(233,338
|
)
|
||||
Total stockholders’ equity
|
29,981
|
16,318
|
||||||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$
|
34,095
|
$
|
20,012
|
Nine months ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Operating Activities:
|
||||||||
Net loss
|
$
|
(15,224
|
)
|
$
|
(12,750
|
)
|
||
Adjustments to reconcile net loss to cash flows used in operating activities:
|
||||||||
Depreciation and amortization
|
383
|
253
|
||||||
993
|
1,036
|
|||||||
Loss on disposal of property and equipment
|
—
|
46
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(164
|
)
|
(249
|
)
|
||||
Inventory
|
(105
|
)
|
(1,371
|
)
|
||||
Other current assets
|
(183
|
)
|
(74
|
)
|
||||
Other assets and liabilities
|
279
|
112
|
||||||
Accounts payable and accrued expenses
|
333
|
(166
|
)
|
|||||
Net cash used in operating activities
|
(13,688
|
)
|
(13,163
|
)
|
||||
Investing Activities:
|
||||||||
Purchases of property and equipment
|
(191
|
)
|
(207
|
)
|
||||
Net cash used in investing activities
|
(191
|
)
|
(207
|
)
|
||||
Financing Activities:
|
||||||||
27,896
|
25,949
|
|||||||
Proceeds from warrant exercises
|
1
|
4,115
|
||||||
Payments on finance lease liability
|
(21
|
)
|
(14
|
)
|
||||
Net cash provided by financing activities
|
27,876
|
30,050
|
||||||
Effect of exchange rate changes on cash
|
(3
|
)
|
(12
|
)
|
||||
Net increase in cash and cash equivalents
|
13,994
|
16,668
|
||||||
Cash and cash equivalents - beginning of period
|
14,437
|
1,279
|
||||||
Cash and cash equivalents - end of period
|
$
|
28,431
|
$
|
17,947
|
||||
Supplemental cash flow information
|
||||||||
Inventory transferred to property, plant and equipment
|
$
|
257
|
$
|
247
|
||||
Equipment acquired through finance lease liability
|
$
|
—
|
$
|
98
|